The reliable evolution of one or multiple KRAS or NRAS mutant subclones in most patients during anti-EGFR therapy further suggest that the population size and mutation rates are sufficiently high to generate many beneficial driver mutations in any metastatic CRC. The gene discussed is NRAS; the disease is colorectal carcinoma.